Patents by Inventor Samuel Hou

Samuel Hou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200046844
    Abstract: A pharmaceutical composition comprising a peptide-polynucleotide complex, and methods of use thereof.
    Type: Application
    Filed: July 1, 2016
    Publication date: February 13, 2020
    Inventors: Samuel A. Wickline, Kirk Hou
  • Publication number: 20190135918
    Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO, Jonathan BACK
  • Publication number: 20180355064
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: May 21, 2018
    Publication date: December 13, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Samuel HOU
  • Publication number: 20180086836
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Application
    Filed: October 19, 2015
    Publication date: March 29, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Rami LISSILAA, Adrian WALMSLEY, Stanislas BLEIN, Romain OLLIER, Samuel HOU, Jeremy LOYAU
  • Publication number: 20170260280
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: November 10, 2016
    Publication date: September 14, 2017
    Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Publication number: 20170145115
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: June 23, 2016
    Publication date: May 25, 2017
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
  • Patent number: 9493563
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: November 15, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Publication number: 20150232559
    Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2 integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.
    Type: Application
    Filed: January 28, 2015
    Publication date: August 20, 2015
    Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
  • Publication number: 20150133640
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 14, 2015
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
  • Patent number: 8975376
    Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: March 10, 2015
    Assignee: Sanofi
    Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
  • Publication number: 20140294824
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Antoine ATTINGER, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Patent number: 8748585
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: June 10, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Publication number: 20130183315
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: July 10, 2012
    Publication date: July 18, 2013
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Publication number: 20130052191
    Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.
    Type: Application
    Filed: February 22, 2011
    Publication date: February 28, 2013
    Applicant: SANOFI
    Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
  • Patent number: 8236315
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 7, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • Publication number: 20090232804
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Application
    Filed: January 23, 2009
    Publication date: September 17, 2009
    Applicant: GLENMARK PHARMACEUTICALS, S.A.,
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger